Cellectis (CLLS) News Today → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free CLLS Stock Alerts $2.99 -0.05 (-1.64%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13, 2024 | americanbankingnews.comCellectis (NASDAQ:CLLS) Receives New Coverage from Analysts at StockNews.comMay 6, 2024 | globenewswire.comCellectis Announces Completion of the Additional Equity Investment by AstraZenecaMay 2, 2024 | globenewswire.comCellectis Appoints Arthur Stril as Interim Chief Financial OfficerMay 1, 2024 | benzinga.comCellectis Stock (NASDAQ:CLLS), Earnings Estimates, EPS, and RevenueApril 29, 2024 | globenewswire.comCellectis Reports Financial Results for the Fourth Quarter and Full Year 2023April 24, 2024 | seekingalpha.comCLLS Cellectis S.A.April 22, 2024 | globenewswire.comCellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsApril 11, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Decline in Thursday TradingApril 10, 2024 | finance.yahoo.comCellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsApril 10, 2024 | globenewswire.comCellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsApril 8, 2024 | globenewswire.comCellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual MeetingApril 1, 2024 | marketbeat.comCellectis S.A. (NASDAQ:CLLS) Sees Significant Decrease in Short InterestCellectis S.A. (NASDAQ:CLLS - Get Free Report) was the recipient of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 679,300 shares, a decline of 6.6% from the February 29th total of 727,500 shares. Based on an average daily trading volume, of 50,500 shares, the days-to-cover ratio is presently 13.5 days.March 27, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday TradingMarch 11, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday TradingFebruary 27, 2024 | marketbeat.comCellectis (NASDAQ:CLLS) Share Price Crosses Below 50 Day Moving Average of $2.99Cellectis (NASDAQ:CLLS) Shares Pass Below 50 Day Moving Average of $2.99February 24, 2024 | finance.yahoo.comCellectis S.A. (CLLS)February 20, 2024 | wsj.comCellectis S.A. ADRFebruary 18, 2024 | marketbeat.comBaillie Gifford & Co. Has $1.84 Million Stock Holdings in Cellectis S.A. (NASDAQ:CLLS)Baillie Gifford & Co. decreased its position in shares of Cellectis S.A. (NASDAQ:CLLS - Free Report) by 18.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,164,009 shares of the biotFebruary 3, 2024 | marketbeat.comCellectis (NASDAQ:CLLS) Stock Price Passes Above Fifty Day Moving Average of $3.02Cellectis (NASDAQ:CLLS) Stock Passes Above 50 Day Moving Average of $3.02February 3, 2024 | finance.yahoo.comMonthly information on share capital and company voting rightsJanuary 26, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, End Week Up 2.6%January 16, 2024 | msn.comCellectis draws down second tranche under EIB credit facilityJanuary 16, 2024 | finance.yahoo.comCellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)December 31, 2023 | marketbeat.comShort Interest in Cellectis S.A. (NASDAQ:CLLS) Decreases By 19.9%Cellectis S.A. (NASDAQ:CLLS - Get Free Report) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 840,900 shares, a decline of 19.9% from the November 30th total of 1,050,000 shares. Based on an average daily trading volume, of 1,860,000 shares, the days-to-cover ratio is presently 0.5 days.December 22, 2023 | finance.yahoo.comCellectis Reports Results from Shareholders Meeting Held on December 22, 2023December 16, 2023 | msn.comCellectis - ADR (CLLS) Price Target Increased by 20.85% to 11.75December 15, 2023 | marketbeat.comCellectis S.A. (NASDAQ:CLLS) Short Interest UpdateCellectis S.A. (NASDAQ:CLLS - Get Free Report) saw a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 1,050,000 shares, a drop of 28.1% from the November 15th total of 1,460,000 shares. Based on an average daily trading volume, of 1,850,000 shares, the days-to-cover ratio is currently 0.6 days.November 17, 2023 | finance.yahoo.comCellectis’ Shareholders Meeting to be Held on December 22, 2023November 15, 2023 | finance.yahoo.comCellectis Announces the execution of the Subsequent Investment Agreement with AstraZenecaNovember 12, 2023 | morningstar.comCellectis SA ADR CLLSNovember 8, 2023 | finance.yahoo.comCellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS), Agenus (AGEN) and OrthoPediatrics (KIDS)November 6, 2023 | seekingalpha.comCellectis Non-GAAP EPS of -$0.58, revenue of $1.88MNovember 3, 2023 | benzinga.comEarnings Preview: CellectisNovember 2, 2023 | finance.yahoo.comCellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual MeetingNovember 1, 2023 | msn.comCellectis - ADR (CLLS) Price Target Increased by 11.03% to 11.29November 1, 2023 | finance.yahoo.comCellectis to Report Third Quarter 2023 Financial Results on November 6, 2023November 1, 2023 | markets.businessinsider.comCellectis Announces Collaboration Agreement With AstraZeneca; To Receive Up To $245 MlnNovember 1, 2023 | theglobeandmail.comBiotech Shares Soar After AstraZeneca Stake & Research CollaborationNovember 1, 2023 | msn.comWhy Is Cancer Player Cellectis Stock Trading Over 100% Higher Today?November 1, 2023 | msn.comAstraZeneca to invest $245m in French biotech company CellectisNovember 1, 2023 | markets.businessinsider.comWhy Is Cellectis (CLLS) Stock Up 175% Today?October 31, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Remain Relatively Flat in Tuesday TradingOctober 31, 2023 | finance.yahoo.comCellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingOctober 25, 2023 | markets.businessinsider.comBlueprint Medicines earnings: here's what Wall Street expectsOctober 24, 2023 | finance.yahoo.comCellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual CongressOctober 16, 2023 | msn.comTelecoms Stocks Lift European Equities Traded in the US as American Depositary Receipts MondayOctober 13, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Decline Friday But End Week Up Nearly 2%October 12, 2023 | finance.yahoo.comCellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)October 3, 2023 | msn.comThese 2 “Strong Buy” Penny Stocks Could Gain Over 500%, Says Baird Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Global crypto currency reset (41 major banks signed up) (Ad)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. CLLS Media Mentions By Week CLLS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLLS News Sentiment▼0.300.42▲Average Medical News Sentiment CLLS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLLS Articles This Week▼01▲CLLS Articles Average Week Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: XFOR News CRDF News CGEN News GNFT News VXRT News ADVM News CRDL News ELEV News VIGL News FENC News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLLS) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersElon’s New Device is About to Shock the WorldInvestorPlaceMost important medical advance in 100 yearsThe Oxford ClubBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist My Default Watchlist Adding Cellectis S.A. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
